Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective ...

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe ...

Regulatory review is underway in multiple additional geographies, including with the European Medicines Agency ... prepared in accordance with GAAP. Amgen discovers, develops, manufactures ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Amgen Inc (Symbol: AMGN), Banco Latinoamericano de Comercio Exterior, S.A. (Symbol: BLX), and Sabra Health Care REIT Inc ...